/
NRXS
$7.14-$0.13 (-1.79%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$90.0M
12M shares
52-week range
$2.20 – $9.33
69% from low
Sector
ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS
Exchange
XASE
CS
Borrow rate
0.43%
Easy to borrow
Price (6 mo)
Loading chart…
Change+$1.14
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $1.9M | $2.7M | $2.7M | $2.5M | $2.7M | $3.6M |
| Cost of revenue | $481.1K | $467.7K | $297.1K | $303.3K | $362.0K | $562.9K |
| Gross profit | $1.4M | $2.3M | $2.4M | $2.2M | $2.3M | $3.0M |
| Gross margin | 75.1% | 82.8% | 88.9% | 87.7% | 86.5% | 84.2% |
| R&D | $166.8K | $203.4K | $225.6K | $169.3K | $206.1K | $493.6K |
| Operating income | −$4.1M | −$3.0M | −$3.4M | −$6.7M | −$7.2M | −$7.8M |
| EBITDA | −$3.6M | −$3.0M | −$4.3M | −$9.2M | −$7.9M | −$7.7M |
| Net income | −$3.7M | −$3.0M | −$4.8M | −$14.6M | −$8.2M | −$7.8M |
| Net margin | -193.0% | -111.3% | -178.0% | -594.6% | -306.8% | -218.5% |
| EPS (diluted) | -0.80 | -0.62 | -0.78 | -2.32 | -1.22 | -0.95 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $10M | $-0.68 | $-0.84–$-0.52 | 2 |
| 2027 | $21M | $-0.06 | $-0.06–$-0.06 | 1 |
| 2028 | $33M | $0.39 | $0.38–$0.40 | 1 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
Neuraxis, Inc.
Neuraxis Inc is a growth-stage medical technology company focused on neuromodulation therapies for chronic and debilitating conditions in the gastrointestinal (GI) digestive system, specifically from disorders of the gut-brain interaction (DGBIs) in pediatrics and adults. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).
www.neuraxis.com- Employees
- 24
- IPO / List date
- Aug 9, 2023
- HQ
- CARMEL, IN
Held by traders on TradeandTell
No one on the platform currently holds NRXS.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 76,954 | $569.5K |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded NRXS yet.
